MDMX: a novel p53‐binding protein with some functional properties of MDM2.

p53 Mutations in Human Cancers

Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018

p53, guardian of the genome

Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649

The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53

Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113

Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53

Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562

T antigen is bound to a host protein in SY40-transformed cells

Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456

The P-loop — a common motif in ATP- and GTP-binding proteins

Saraste, M., Sibbald, P. R., & Wittinghofer, A. (1990) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(90)90281-f · Cited by 2,099

Amplification of a gene encoding a p53-associated protein in human sarcomas

Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949

Inhibition of Mdmx (Mdm4) in vivo induces anti-obesity effects

Kon, N., Wang, D., Li, T., Jiang, L., Qiang, L., & Gu, W. (2018) · Oncotarget · doi:10.18632/oncotarget.23837 · Cited by 17

Regulation of MDM4 (MDMX) function by p76MDM2: a new facet in the control of p53 activity

Giglio, S., Mancini, F., Pellegrino, M., Conza, G. D., Puxeddu, E., Sacchi, A., Pontecorvi, A., & Moretti, F. (2010) · Oncogene · doi:10.1038/onc.2010.324 · Cited by 17

Downregulation of Mdm2 and Mdm4 enhances viral gene expression during adenovirus infection

Yang, H., Zheng, Z., Zhao, L., Li, Q., & Liao, D. (2012) · Cell Cycle · doi:10.4161/cc.11.3.19052 · Cited by 18

Structure-based designing efficient peptides based on p53 binding site residues to disrupt p53-MDM2/X interaction

Rasafar, N., Barzegar, A., & Aghdam, E. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-67510-8 · Cited by 15

Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4)

Macchiarulo, A., Giacchè, N., Carotti, A., Moretti, F., & Pellicciari, R. (2011) · MedChemComm · doi:10.1039/c0md00238k · Cited by 16

MDM4rs4245739 A > C polymorphism correlates with reduced overall cancer risk in a meta-analysis of 69477 subjects

Xu, C., Zhu, J., Fu, W., Liang, Z., Song, S., Zhao, Y., Lyu, L., Zhang, A., He, J., & Duan, P. (2016) · Oncotarget · doi:10.18632/oncotarget.12326 · Cited by 16

TP53 and therapy-related myeloid neoplasms

Chung, J., Sallman, D. A., & Padron, E. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.02.009 · Cited by 16

A Single Conserved Amino Acid Residue as a Critical Context-Specific Determinant of the Differential Ability of Mdm2 and MdmX RING Domains to Dimerize

Kosztyu, P., Slaninová, I., Valčíková, B., Verlande, A., Müller, P., Palecek, J. J., & Uldrijan, S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00390 · Cited by 15

XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer

Roh, J., Park, J. Y., & Kim, E. H. (2014) · APOPTOSIS · doi:10.1007/s10495-014-1026-8 · Cited by 16

Mechanistic target of rapamycin inhibition with rapamycin induces autophagy and correlative regulation in white shrimp (Litopenaeus vannamei)

Liu, X., Wang, M., Sun, G.-Q., Wang, B., Jiang, K., Shao, J., Qi, C., Zhao, W., Han, S.-Y., Liu, M., et al. (2018) · Aquaculture Nutrition · doi:10.1111/anu.12688 · Cited by 16

Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors

Stefaniak, J., Lewis, A. M., Conole, D., Galan, S. R. G., Bataille, C. J. R., Wynne, G. M., Castaldi, M. P., Lundbäck, T., Russell, A. J., & Huber, K. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00665 · Cited by 16

Doxorubicin and 5-fluorouracil induced accumulation and transcriptional activity of p53 are independent of the phosphorylation at serine 15 in MCF-7 breast cancer cells

Balmer, M. T., Katz, R. D., Liao, S., Goodwine, J. S., & Gal, S. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29112 · Cited by 16

MDM2 in breast cancer

Toi, M., Saji, S., Suzuki, A., Yamamoto, Y., & Tominaga, T. (1997) · Breast Cancer · doi:10.1007/bf02966519 · Cited by 16

A Transcriptionally Inactive E2F-1 Targets the MDM Family of Proteins for Proteolytic Degradation

Strachan, G. D., Rallapalli, R., Pucci, B., Lafond, T. P., & Hall, D. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103765200 · Cited by 16

Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts

Lenos, K., de Lange, J., Teunisse, A. F., Lodder, K., Verlaan-de Vries, M., Wiercinska, E., van der Burg, M. J., Szuhai, K., & Jochemsen, A. G. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-111 · Cited by 16

MDMX in Cancer: A Partner of p53 and a p53-Independent Effector

Wu, L., Yan, Y., Huang, Q., & Zheng, D. (2024) · Biologics · doi:10.2147/btt.s436629 · Cited by 17

Tumorigenesis promotes Mdm4-S overexpression

Pant, V., Larsson, C. A., Aryal, N. K., Xiong, S., You, M. J., Quintás‐Cardama, A., & Lozano, G. (2017) · Oncotarget · doi:10.18632/oncotarget.15552 · Cited by 15

MiR-483-3p inhibition ameliorates myocardial ischemia/reperfusion injury by targeting the MDM4/p53 pathway

Zhang, H., Wang, J., Du, A., & Li, Y. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.06.014 · Cited by 15

The Janus Face of p53-Targeting Ubiquitin Ligases

Hao, Q., Chen, Y., & Zhou, X. Y. (2020) · Cells · doi:10.3390/cells9071656 · Cited by 16

Association of rs11801299 and rs1380576 polymorphisms at MDM4 with risk, clinicopathological features and prognosis in patients with retinoblastoma

Yu, F., Jiang, Z., & Song, A.-P. (2019) · Cancer Epidemiology · doi:10.1016/j.canep.2018.12.010 · Cited by 15

Real-Time Quantitative PCR Analysis of Regions Involved in Gene Amplification Reveals Gene Overdose in Low-Grade Astrocytic Gliomas

Arjona, D., Bello, M. J., Alonso, M. E., Isla, A., de Campos, J. M., Vaquero, J., Sarasa, J. L., Gutiérrez, M., & REY, J. A. (2005) · Diagnostic Molecular Pathology · doi:10.1097/01.pas.0000177799.58336.1a · Cited by 15

Cell Proliferation and Apoptosis—Key Players in the Lung Aging Process

Áncer‐Rodríguez, J., Gopar‐Cuevas, Y., García‐Aguilar, K., Chávez-Briones, M.-D.-L., Miranda-Maldonado, I. C., Ancer-Arellano, A., Ortega‐Martínez, M., & Jaramillo‐Rangel, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147867 · Cited by 16

MDM4 binds ligands via a mechanism in which disordered regions become structured

Sanchez, M. C., Renshaw, J., Davies, G. M., Barlow, P. N., & Vogtherr, M. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.05.058 · Cited by 14

The overexpression of MDM4: an effective and novel predictor of gastric adenocarcinoma lymph node metastasis

Bao, J., Nanding, A., Song, H., Xu, R., Qu, G., & Xue, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.11971 · Cited by 14

MDMX Regulates Transcriptional Activity of p53 and FOXO Proteins to Stimulate Proliferation of Melanoma Cells

Heijkants, R. C., Teunisse, A. F. A. S., de Jong, D., Glinkina, K., Mei, H., Kiełbasa, S. M., Szuhai, K., & Jochemsen, A. G. (2022) · Cancers · doi:10.3390/cancers14184482 · Cited by 13

Targeting the conformational transitions of MDM2 and MDMX: Insights into key residues affecting p53 recognition

Carotti, A., Macchiarulo, A., Giacchè, N., & Pellicciari, R. (2009) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22464 · Cited by 13

ChIP for Identification of p53 Responsive DNA Promoters

Liao, J., & Lu, H. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-236-0_17 · Cited by 13

CPSF4 promotes triple negative breast cancer metastasis by upregulating MDM4

Lee, K., Zheng, Q., Lu, Q., Xu, F., Qin, G., Zhai, Q., Hong, R., Chen, M., Deng, W., & Wang, S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00565-9 · Cited by 13

Searching for Dual Inhibitors of the MDM 2‐p53 and MDMX ‐p53 Protein–Protein Interaction by a Scaffold‐Hopping Approach

Zaytsev, A. V., Dodd, B., Magnani, M., Ghiron, C., Golding, B. T., Griffin, R. J., Liu, J., Lü, X., Micco, I., Newell, D. R., et al. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12474 · Cited by 13

HDMX regulates p53 activity and confers chemoresistance to 3-Bis(2-chloroethyl)-1-nitrosourea

Jin, G., Cook, S., Cui, B., Chen, W., Keir, S. T., Killela, P. J., Di, C., Payne, C. A., Gregory, S. G., McLendon, R. E., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq045 · Cited by 13

Variations within 3′-UTR of MDM4 gene contribute to clinical outcomes of advanced non-small cell lung cancer patients following platinum-based chemotherapy

Yang, Y., Gao, W., Ding, X., Xu, W., Liu, D., Su, B., & Sun, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.10771 · Cited by 13

Genome-wide association study identifies zonisamide responsive gene in Parkinson’s disease patients

Cha, P.-C., Satake, W., Ando-Kanagawa, Y., Yamamoto, K., Murata, M., & Toda, T. (2020) · Journal of Human Genetics · doi:10.1038/s10038-020-0760-8 · Cited by 13

MDM4 genetic variants and risk of gastric cancer in an eastern chinese population

Wang, M., Jia, M., He, J., Zhou, F., Qiu, L., Sun, M.-H., Yang, Y.-J., Wang, J.-C., Li, J., Wang, Y.-N., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14666 · Cited by 13

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation

Hirose, M., Yamato, K., Endo, S., Saito, R., Ueno, T., Hirai, S., Suzuki, H., Abei, M., Natori, Y., & Hyodo, I. (2014) · Oncoscience · doi:10.18632/oncoscience.103 · Cited by 14

Data mining the p53 pathway in the Fugu genome: evidence for strong conservation of the apoptotic pathway

Bras, M. L., Bensaad, K., & Soussi, T. (2003) · Oncogene · doi:10.1038/sj.onc.1206424 · Cited by 13

Understanding the interaction of 14‐3‐3 proteins with h DMX and h DM2: a structural and biophysical study

Srdanović, S., Wolter, M., Trinh, C. H., Ottmann, C., Warriner, S. L., & Wilson, A. J. (2022) · FEBS Journal · doi:10.1111/febs.16433 · Cited by 13

miR‑205 suppresses cell migration, invasion and EMT of colon cancer by targeting mouse double minute 4

Fan, Y., & Wang, K. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11150 · Cited by 12

The MDMX Acidic Domain Uses Allovalency to Bind Both p53 and MDMX

Fenton, M. J., Borcherds, W. M., Chen, L., Anbanandam, A., Levy, R., Chen, J., & Daughdrill, G. W. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167844 · Cited by 12

Mdm2 and MdmX Involvement in Human Cancer

Berberich, S. J. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_15 · Cited by 12

Role of the N-terminal lid in regulating the interaction of phosphorylated MDMX with p53

Chan, J. V., Koh, D. X. P., Liu, Y., Joseph, T. L., Lane, D. P., Verma, C. S., & Tan, Y. S. (2017) · Oncotarget · doi:10.18632/oncotarget.22829 · Cited by 12

S100A1 blocks the interaction between p53 and mdm2 and decreases cell proliferation activity

Dowarha, D., Chou, R., & Yu, C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234152 · Cited by 12

Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53

Brown, D. W., Beatty, P. H., & Lewis, J. D. (2022) · Cancers · doi:10.3390/cancers14215176 · Cited by 13

Analysis and Design of Piezoelectric Braille Display

Smithmaitrie, P. (2009) · InTech eBooks · doi:10.5772/7391 · Cited by 12

Structure of Human MDM4 N-Terminal Domain Bound to a Single-Domain Antibody

Yu, G. W., Vaysburd, M., Allen, M. D., Settanni, G., & Fersht, A. R. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.11.043 · Cited by 12

P53 upregulation by USP7-engaging molecular glues

Li, Z., Wang, Z., Zhong, C., Zhang, H., Liu, R., An, P., Ma, Z., Lü, J., Pan, C., Zhang, Z., et al. (2024) · 中国科学通报：英文版 · doi:10.1016/j.scib.2024.04.017 · Cited by 13

Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids

Chee, S. M. Q., Wongsantichon, J., Siau, J. W., Thean, D., Ferrer, F. J., Robinson, R. C., Lane, D. P., Brown, C. J., & Ghadessy, F. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189379 · Cited by 11

Synthetic 10FN3-based mono- and bivalent inhibitors of MDM2/X function

Lau, S. Y., Siau, J. W., Sobota, R. M., Wang, C. I., Zhong, P., Lane, D. P., & Ghadessy, F. J. (2018) · Protein Engineering Design and Selection · doi:10.1093/protein/gzy018 · Cited by 11

Perspectives on drug discovery strategies based on IDPs

Fuertes, G., Nevola, L., & Esteban-Martín, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816348-1.00009-0 · Cited by 11

Calpain-mediated degradation of MDMx/MDM4 contributes to HIV-induced neuronal damage

Colacurcio, D. J., Yeager, A. M., Kolson, D. L., Jordan‐Sciutto, K. L., & Akay, C. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2013.10.003 · Cited by 11

Probing Difference in Binding Modes of Inhibitors to MDMX by Molecular Dynamics Simulations and Different Free Energy Methods

Shi, S., Zhang, S., & Zhang, Q. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141409 · Cited by 10

Identification of a novel population in high-grade oligodendroglial tumors not deleted on 1p/19q using array CGH

Talagas, M., Marcorelles, P., Uguen, A., Redon, S., Quintin‐Roué, I., Costa, S., Férec, C., Morel, F., Hieu, P. D., & Braekeleer, M. D. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0909-1 · Cited by 10

YAF2 promotes TP53-mediated genotoxic stress response via stabilization of PDCD5

Park, S., Choi, H.-K., Jo, S., Seo, J., Han, E.-J., Choi, K., Jeong, J., Choi, Y., & Yoon, H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.01.006 · Cited by 11

Deletion of ARGLU1 causes global defects in alternative splicing in vivo and mouse cortical malformations primarily via apoptosis

Yao, F., Huang, S., Liu, J., Tan, C., Xu, M., Wang, D., Huang, M., Zhu, Y., Huang, X., & He, S. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06071-w · Cited by 10

Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable

Miyagi, Y. (2011) · Oncology Reports · doi:10.3892/or.2011.1270 · Cited by 10

Distinct target genes and effector processes appear to be critical for p53-activated responses to acute DNA damage versus p53-mediated tumour suppression

Valent, L., & Strasser, A. (2013) · Biodiscovery · doi:10.7750/biodiscovery.2013.8.3 · Cited by 12

p53 in the Clinics

Hainaut, P. L., Wiman, K. G., & Olivier, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8 · Cited by 10

Focused Library Generator: case of Mdmx inhibitors

Xia, Z., Karpov, P., Popowicz, G. M., & Tetko, I. V. (2019) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-019-00242-8 · Cited by 10

Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild‑type TP53 colon and gastric cancer cells with aberrant KRAS signaling

Wang, X., Yamamoto, Y., Imanishi, M., Zhang, X., Sato, M., Sugaya, A., Hirose, M., Endo, S., Natori, Y., Moriwaki, T., et al. (2021) · Oncology Letters · doi:10.3892/ol.2021.12819 · Cited by 10

The spliceosome factor sart3 regulates hematopoietic stem/progenitor cell development in zebrafish through the p53 pathway

Zhao, Y., Wu, M., Li, J., Meng, P., Chen, J., Huang, Z., Xu, J., Wen, Z., Zhang, W., & Zhang, Y. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04215-4 · Cited by 10

A site-directed mutagenesis study of the MdmX RING domain

Egorova, O., & Sheng, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.04.065 · Cited by 10

Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice

Tian, H., Tackmann, N. R., Jin, A., Zheng, J., & Zhang, Y. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000122 · Cited by 9

A p53 transcriptional signature in primary and metastatic cancers derived using machine learning

Keshavarz-Rahaghi, F., Pleasance, E., Kolisnik, T., & Jones, S. J. M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.987238 · Cited by 8

Identification and expression of a novel MDM4 splice variant in human glioma

Wang, X., Sheng, P. X., Guo, X., Wang, J., Hou, L.-J., Hu, G., Luo, C., Dong, Y., & Lu, Y. (2013) · Brain Research · doi:10.1016/j.brainres.2013.07.054 · Cited by 9

p53 Regulation Goes Live--Mdm2 and MdmX Co-Star: Lessons Learned from Mouse Modeling

Tollini, L. A., & Zhang, Y. (2012) · Genes & Cancer · doi:10.1177/1947601912454732 · Cited by 9

Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99

Lee, X. A., Verma, C. S., & Sim, A. Y. L. (2017) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25310 · Cited by 9

Environment-sensitive turn-on fluorescent probes for p53–MDM2 protein–protein interaction

Liu, T., Jiang, Y., Liu, Z., Li, J., Fang, K., Zhuang, C., Du, L., Fang, H., Sheng, C., & Li, M. (2017) · MedChemComm · doi:10.1039/c7md00287d · Cited by 9

Clinical and Genetic Characteristics of Thymoma Patients With Autoimmune Hepatitis and Myocarditis

Yu, X., Yu, L., Du, X., Yu, Z., Yang, X., & Jiang, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.746304 · Cited by 9

Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies

Ernst, P., & Heidel, F. H. (2021) · Cancers · doi:10.3390/cancers13040612 · Cited by 9

Mdm2 Plays a Positive Role as an Effector of p53-Dependent Responses

Giono, L. E., & Manfredi, J. J. (2007) · Cell Cycle · doi:10.4161/cc.6.17.4647 · Cited by 9

Targeting p53 activation: Recent therapeutic advances in cancer and diabetic macular edema

Wang, Z., Zhang, S., Mélita, I. L., & Zhao, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117909 · Cited by 10

Elaboration of Non-naturally Occurring Helical Tripeptides as p53–MDM2/MDMX Interaction Inhibitors

Su, A., Tabata, Y., Aoki, K., Sada, A., Ohki, R., Nagatoishi, S., Tsumoto, K., Wang, S., Otani, Y., & Ohwada, T. (2021) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c21-00238 · Cited by 8

Canonical Wnt: a safeguard and threat for erythropoiesis

Krimpenfort, R. A., & Nethe, M. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004845 · Cited by 11

A feedback circuit of miR-34a/MDM4/p53 regulates apoptosis in chronic lymphocytic leukemia cells

Cao, L., Liu, Y., Lu, J., Miao, Y., Du, X., Wang, R., Yang, H., Xu, W., Li, J., & Fan, L. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-1710 · Cited by 8

MDM4 Isoform Expression in Melanoma Supports an Oncogenic Role for MDM4-A

Alatawi, A. S. S., Kho, S. J., & Markey, M. P. (2021) · Journal of Skin Cancer · doi:10.1155/2021/3087579 · Cited by 8

1H, 15N and 13C backbone resonance assignments of the acidic domain of the human MDMX protein

Song, Q., Liu, X., & Rainey, J. K. (2022) · Biomolecular NMR Assignments · doi:10.1007/s12104-022-10081-8 · Cited by 8

Pharmacological inhibition of MDM4 alleviates pulmonary fibrosis

Mei, Q., Yang, Z., Xiang, Z., Zuo, H., Zhou, Z., Dong, X., Zhang, L., Song, W., Wang, Y., Hu, Q., et al. (2023) · Theranostics · doi:10.7150/thno.81993 · Cited by 10

Ubiquitin E3 ligases controlling p53 stability

Lee, S. W., Seong, M. W., Jeon, Y. J., & Chung, C. H. (2012) · Animal Cells and Systems · doi:10.1080/19768354.2012.688769 · Cited by 9

Ranking the Binding Energies of p53 Mutant Activators and Their ADMET Properties

Omar, S. I., & Tuszyński, J. A. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12480 · Cited by 8

Amniotic Fluid Cells, Stem Cells, and p53: Can We Stereotype p53 Functions?

Rodrigues, M., Blattner, C., & Stuppia, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092236 · Cited by 8

MDM4 expression in fibrolamellar hepatocellular carcinoma

Karki, A., Putra, J., Kim, S. M., LaQuaglia, M. P., Pérez‐Atayde, A. R., Sadri‐Vakili, G., & Vakili, K. (2019) · Oncology Reports · doi:10.3892/or.2019.7241 · Cited by 8

Proximity-induced amino-yne reaction for selective MDM4 conjugation via propargylated sulfonium

Lian, C., Li, Y., Hou, Z., Zhong, W., Tian, Y., Yin, F., Li, Z., Zhou, D., & Wang, R. Y. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.04.015 · Cited by 8

Gatekeepers of the Guardian: p53 Regulation by Post-Translational Modification, MDM2 and MDMX

Wahl, G. M., Stommel, J. M., Krummel, K. A., & Wade, M. R. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_4 · Cited by 9

Association of MDM4 Gene rs4245739 Polymorphism with the Risk and Clinical Characteristics of Colorectal Cancer in a Chinese Han Population

Zhao, D.-M., Diao, Y., & Xu, Q. (2020) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s260209 · Cited by 7

Identification of Small Molecules Affecting p53-MDM2/MDMX Interaction by Fluorescence Polarization

Zhang, Q., & Lu, H. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-236-0_8 · Cited by 7

The Role of MDM4 SNP34091 A>C Polymorphism in Cancer: A Meta-Analysis on 19,328 Patients and 51,058 Controls

Jin, X., Zhao, W., Zheng, M., Zhou, P., & Niu, T. (2016) · The International Journal of Biological Markers · doi:10.5301/jbm.5000228 · Cited by 7

MDM2/P53 Inhibitors as Sensitizing Agents for Cancer Chemotherapy

Zhu, Y. Y., Wang, H., & Thuraisamy, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00015-8 · Cited by 7

A concise review on MDM2 inhibitors and recent progress in radiopharmaceutical development for imaging MDM2 expression in tumors with PET or SPECT

Siriki, A., Ragland, G., Vasireddy, J., & Chitneni, S. K. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130394 · Cited by 7

p53 Phosphomimetics Preserve Transient Secondary Structure but Reduce Binding to Mdm2 and MdmX

Levy, R., Gregory, E., Borcherds, W. M., & Daughdrill, G. W. (2019) · Biomolecules · doi:10.3390/biom9030083 · Cited by 7

Cryptic in vitro ubiquitin ligase activity of HDMX towards p53 is probably regulated by an induced fit mechanism

Calderón-González, K. G., Medina‐Medina, I., Hároníková, L., Hernychová, L., Bonczek, O., Uhrík, L., Hrabal, V., Vojtěšek, B., Fåhræus, R., Hernández‐Monge, J., et al. (2022) · Bioscience Reports · doi:10.1042/bsr20220186 · Cited by 6

MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin

Zhao, H., Xie, Y., Xing, R., Sun, M., Chi, F., & Zeng, Y. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0325-9 · Cited by 6

The fate of murine double minute X (MdmX) is dictated by distinct signaling pathways through murine double minute 2 (Mdm2)

Hauck, P. M., Wolf, E. R., Olivos, D. J., McAtarsney, C. P., & Mayo, L. D. (2017) · Oncotarget · doi:10.18632/oncotarget.22320 · Cited by 6

Studying Homo-oligomerization and Hetero-oligomerization of MDMX and MDM2 Proteins in Single Living Cells by Using In Situ Fluorescence Correlation Spectroscopy

Li, F., Yu, S., Huang, X., Dong, C., & Ren, J. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00153 · Cited by 6

Molecular and Biochemical Techniques for Deciphering p53-MDM2 Regulatory Mechanisms

Karakostis, K., López, I., Peña-Balderas, A. M., Fåhareus, R., & Olivares‐Illana, V. (2020) · Biomolecules · doi:10.3390/biom11010036 · Cited by 7

Targeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies

Wu, H. H., Leng, S., Eisenstat, D. D., Sergi, C. M., & Leng, R. P. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00907-x · Cited by 6

Virtual Screening for DNA Repair Inhibitors

Barakat, K., & Tuszyński, J. A. (2011) · InTech eBooks · doi:10.5772/24436 · Cited by 5

Intra molecular interactions in the regulation of p53 pathway

Chen, J. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.09.23 · Cited by 5

Therapeutic considerations for Mdm2: not just a one trick pony

Lehman, J. A., Eitel, J. A., Batuello, C. N., & Mayo, L. D. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.11.1309 · Cited by 6

The amino-terminus of the E2F-1 transcription factor inhibits DNA replication of autonomously replicating plasmids in mammalian cells

Stubbs, M. C., & Hall, D. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205473 · Cited by 5

p53 Tumor Suppressor Protein

Ashcroft, M. A., & Vousden, K. H. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-230-2_7 · Cited by 5

Mechanistic Role of the Mdm2/MdmX Lid Domain in Regulating Their Interactions with p53

Wei, Q., Li, C., Tang, Y., Bai, J., Wang, L., Liu, J., Su, Z., & Cheng, X. (2025) · Biomolecules · doi:10.3390/biom15050642 · Cited by 4

Comparative study of the p53-mdm2 and p53-MDMX interfaces

Böttger, V., Böttger, A., Garcia-Echeverria, C., Ramos, Y. F., van der Eb, A. J., Jochemsen, A. G., & Lane, D. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202281 · Cited by 189

Isolation and Identification of the Human Homolog of a New p53-Binding Protein, Mdmx

Shvarts, A., Bazuine, M., Dekker, P., Ramos, Y. F., Steegenga, W. T., Merckx, G., van Ham, R. C. A., van Oordt, C. W. M. D. H., van der Eb, A. J., & Jochemsen, A. G. (1997) · Genomics · doi:10.1006/geno.1997.4775 · Cited by 152

Identification of a domain within MDMX‐S that is responsible for its high affinity interaction with p53 and high‐level expression in mammalian cells

Rallapalli, R., Strachan, G. D., Tuan, R. S., & Hall, D. J. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10535 · Cited by 45

MdmX Is Required for p53 Interaction with and Full Induction of the Mdm2 Promoter after Cellular Stress

Biderman, L., Poyurovsky, M. V., Assia, Y., Manley, J. L., & Prives, C. L. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06150-11 · Cited by 27

Constitutive mdmx Expression During Cell Growth, Differentiation, and DNA Damage

Jackson, M. W., & Berberich, S. J. (1999) · DNA and Cell Biology · doi:10.1089/104454999314971 · Cited by 27